🚀 VC round data is live in beta, check it out!
Dare Bioscience Valuation Multiples
Discover revenue and EBITDA valuation multiples for Dare Bioscience and similar public comparables like Genenta Science, AlzeCure Pharma, Marker Therapeutics, Argenica Therapeutics and more.
Dare Bioscience Overview
About Dare Bioscience
Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women’s health.
Founded
2005
HQ
Employees
23
Website
Financials (LTM)
EV
$3M
Dare Bioscience Financials
Dare Bioscience reported last 12-month revenue of $762K.
In the same LTM period, Dare Bioscience generated $543K in gross profit and had net loss of ($16M).
Revenue (LTM)
Dare Bioscience P&L
In the most recent fiscal year, Dare Bioscience reported revenue of $1M and EBITDA of ($12M).
Dare Bioscience expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $762K | XXX | $1M | XXX | XXX | XXX |
| Gross Profit | $543K | XXX | $734K | XXX | XXX | XXX |
| Gross Margin | 71% | XXX | 71% | XXX | XXX | XXX |
| EBITDA | — | XXX | ($12M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (1157%) | XXX | XXX | XXX |
| EBIT Margin | (2066%) | XXX | (1314%) | XXX | XXX | XXX |
| Net Profit | ($16M) | XXX | ($13M) | XXX | XXX | XXX |
| Net Margin | (2045%) | XXX | (1301%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Dare Bioscience Stock Performance
Dare Bioscience has current market cap of $23M, and enterprise value of $3M.
Market Cap Evolution
Dare Bioscience's stock price is $1.61.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3M | $23M | 0.0% | XXX | XXX | XXX | $-0.94 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialDare Bioscience Valuation Multiples
Dare Bioscience trades at 3.8x EV/Revenue multiple, and (0.2x) EV/EBITDA.
EV / Revenue (LTM)
Dare Bioscience Financial Valuation Multiples
As of April 5, 2026, Dare Bioscience has market cap of $23M and EV of $3M.
Equity research analysts estimate Dare Bioscience's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Dare Bioscience has a P/E ratio of (1.5x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $23M | XXX | $23M | XXX | XXX | XXX |
| EV (current) | $3M | XXX | $3M | XXX | XXX | XXX |
| EV/Revenue | 3.8x | XXX | 2.8x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (0.2x) | XXX | XXX | XXX |
| EV/EBIT | (0.2x) | XXX | (0.2x) | XXX | XXX | XXX |
| EV/Gross Profit | 5.3x | XXX | 3.9x | XXX | XXX | XXX |
| P/E | (1.5x) | XXX | (1.7x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (0.3x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Dare Bioscience Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Dare Bioscience Margins & Growth Rates
Dare Bioscience's revenue in the last 12 month declined by (100%).
Dare Bioscience's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.6M for the same period.
Dare Bioscience Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | (100%) | XXX | (100%) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (1157%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (49%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.6M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 1431% | XXX | 851% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 706% | XXX | 536% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 1387% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Dare Bioscience Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Genenta Science | XXX | XXX | XXX | XXX | XXX | XXX |
| AlzeCure Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Marker Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Argenica Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Initiator Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Dare Bioscience M&A Activity
Dare Bioscience acquired XXX companies to date.
Last acquisition by Dare Bioscience was on XXXXXXXX, XXXXX. Dare Bioscience acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Dare Bioscience
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialDare Bioscience Investment Activity
Dare Bioscience invested in XXX companies to date.
Dare Bioscience made its latest investment on XXXXXXXX, XXXXX. Dare Bioscience invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Dare Bioscience
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Dare Bioscience
| When was Dare Bioscience founded? | Dare Bioscience was founded in 2005. |
| Where is Dare Bioscience headquartered? | Dare Bioscience is headquartered in United States. |
| How many employees does Dare Bioscience have? | As of today, Dare Bioscience has over 23 employees. |
| Who is the CEO of Dare Bioscience? | Dare Bioscience's CEO is Sabrina Martucci Johnson. |
| Is Dare Bioscience publicly listed? | Yes, Dare Bioscience is a public company listed on Nasdaq. |
| What is the stock symbol of Dare Bioscience? | Dare Bioscience trades under DARE ticker. |
| When did Dare Bioscience go public? | Dare Bioscience went public in 2014. |
| Who are competitors of Dare Bioscience? | Dare Bioscience main competitors are Genenta Science, AlzeCure Pharma, Marker Therapeutics, Argenica Therapeutics. |
| What is the current market cap of Dare Bioscience? | Dare Bioscience's current market cap is $23M. |
| What is the current revenue of Dare Bioscience? | Dare Bioscience's last 12 months revenue is $762K. |
| What is the current revenue growth of Dare Bioscience? | Dare Bioscience revenue growth (NTM/LTM) is (100%). |
| What is the current EV/Revenue multiple of Dare Bioscience? | Current revenue multiple of Dare Bioscience is 3.8x. |
| Is Dare Bioscience profitable? | No, Dare Bioscience is not profitable. |
| What is the current net income of Dare Bioscience? | Dare Bioscience's last 12 months net income is ($16M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.